3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
3
Lymphoid
3
Other
2
Head & Neck
2
Gastrointestinal
2
CNS
2
Tumor-Agnostic
1
NET
1
Gynecologic
1
Endocrine
1
Conditions
Brain Neoplasms
2
Spinal Cord Neoplasms
1
Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
Temozolomide
123
Radiotherapy
47
Bevacizumab
46
Lomustine
25
Radiation
20
Nivolumab
17
Irinotecan
16
Carboplatin
16
Cyclophosphamide
14
Granulocyte-Macrophage Colony-Stimulating Factor
13
pembrolizumab
11
dabrafenib
10
Trastuzumab
10
Surgical Procedures, Operative
10
Capecitabine
10
paclitaxel-Angiopep-2 conjugate
8
TIC10 compound
8
Paclitaxel
8
Gemcitabine
8
Carmustine
8
trametinib
7
Topotecan
7
IL13-PE38
7
Everolimus
7
Drug Therapy
7
Aminolevulinic Acid
7
AZD 6244
7
3-Iodobenzylguanidine
7
fludarabine
6
enzastaurin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
RRx-001
×
CNS
×
Clear all
NCT04525014
2024-10-31
PIRATE
EpicentRx, Inc.
Phase 1
Terminated
2 enrolled
NCT02215512
2021-11-03
BRAINSTORM
EpicentRx, Inc.
Phase 1
Completed
29 enrolled